Skip to main content

Branded

  • Fifty-nine percent of nasal allergy sufferers report sleeping problems, while 35% treat symptoms, survey finds

    LANDOVER, Md. — More than half of people with nasal allergies report problems sleeping, while slightly more than a third proactively treat their symptoms, according to a new survey.

    The Asthma and Allergy Foundation of America and Teva Respiratory released results of the survey, showing sleeping problems among 59% of sufferers, while 48% said symptoms like congestion and sneezing interrupted a partner's sleep.

  • Parents often complicit in teens' prescription drug abuse, study finds

    NEW YORK — A dramatic jump in the rates of misuse of prescription stimulants over the past four years is linked to lax attitudes on the part of parents, according to a new study, though misuse and abuse of prescription opioids has remained flat.

  • FDA approves drug for opioid-induced constipation

    BETHESDA, Md. — The Food and Drug Administration has approved a new drug for constipation related to use of opioid painkillers made by Sucampo Pharmaceuticals and Takeda Pharmaceuticals, the drug makers said.

  • Warner Chilcott receives FDA approval for Minastrin 24 FE

    DUBLIN — The Food and Drug Administration has approved a new contraceptive drug made by Warner Chilcott, the drug maker said.

    Warner Chilcott announced the approval of Minastrin 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) for prevention of pregnancy.

    The drug maker said an unnamed third-party company would manufacture the drug, but it did not expect to launch it this year.

     

  • FDA approves Alcon's Simbrinza

    BASEL, Switzerland — The Food and Drug Administration has approved a drug made by Alcon, the drug maker said.

  • Nearly one-third of women don't fill new osteoporosis prescriptions, study finds

    PASADENA, Calif. — A new study by Kaiser Permanente finds that a large percentage of women with osteoporosis fail to pick up new prescriptions for the condition.

  • Actavis relaunches generic contraceptive

    PARSIPPANY, N.J. — A federal court ruling has allowed Actavis to relaunch a generic contraceptive drug, the company said.

  • Changes to REMS to allow dispensing of Vivus obesity drug in retail

    MOUNTAIN VIEW, Calif. — The Food and Drug Administration has approved a modification to a program added to the labeling of an obesity drug to ensure patient safety.

    Vivus announced that the FDA had approved changes to the risk evaluation and mitigatin strategy for Qsymia (phentermine and topiramate) extended-release capsules. The amendment to the REMS allows the drug to be dispensed through certified retail pharmacies in addition to the existing network of mail-order pharmacies.

X
This ad will auto-close in 10 seconds